Aspira Women’s Health (NASDAQ:AWH) Now Covered by StockNews.com

Research analysts at StockNews.com started coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a research note issued to investors on Tuesday. The brokerage set a “hold” rating on the stock.

Separately, Alliance Global Partners reduced their price objective on shares of Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating on the stock in a research note on Wednesday, August 14th.

Aspira Women’s Health Trading Down 1.1 %

Shares of NASDAQ:AWH opened at $0.74 on Tuesday. The stock has a market capitalization of $11.90 million, a P/E ratio of -0.51 and a beta of 1.44. Aspira Women’s Health has a 1-year low of $0.71 and a 1-year high of $5.65. The business has a 50-day moving average price of $0.85 and a two-hundred day moving average price of $1.38.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. boosted its stake in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 236,396 shares of the company’s stock after buying an additional 111,022 shares during the period. B. Riley Wealth Advisors Inc. owned approximately 1.90% of Aspira Women’s Health worth $352,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 12.19% of the company’s stock.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.